Core Laboratories Inc.CLBEarnings & Financial Report
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Revenue
$134.4M
Gross Profit
$27.6M
Operating Profit
$19.8M
Net Profit
$11.7M
Gross Margin
20.5%
Operating Margin
14.7%
Net Margin
8.7%
YoY Growth
7.2%
EPS
$0.25
Core Laboratories Inc. Q3 FY2024 Financial Summary
Core Laboratories Inc. reported revenue of $134.4M (up 7.2% YoY) for Q3 FY2024, with a net profit of $11.7M (up 26.9% YoY) (8.7% margin). Cost of goods sold was $106.8M, operating expenses totaled $7.8M.
Key Financial Metrics
| Total Revenue | $134.4M |
|---|---|
| Net Profit | $11.7M |
| Gross Margin | 20.5% |
| Operating Margin | 14.7% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Core Laboratories Inc. Q3 FY2024 revenue of $134.4M breaks down across 2 segments, led by Services at $98.8M (73.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Services | $98.8M | 73.5% |
| Products | $35.6M | 26.5% |
Core Laboratories Inc. Revenue by Segment — Quarterly Trend
Core Laboratories Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and Products) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Services | — | $107.0M | $101.1M | $96.2M |
| Products | — | $31.3M | $33.4M | $33.9M |
Core Laboratories Inc. Annual Revenue by Year
Core Laboratories Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $526.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $526.5M |
| 2024 | $523.8M |
Core Laboratories Inc. Quarterly Revenue & Net Profit History
Core Laboratories Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $121.8M | -1.4% | $5.1M | 4.2% |
| Q4 FY2025 | $138.3M | +7.0% | $4.9M | 3.6% |
| Q3 FY2025 | $134.5M | +0.1% | $14.2M | 10.6% |
| Q2 FY2025 | $130.2M | -0.3% | $10.6M | 8.2% |
| Q1 FY2025 | $123.6M | -4.7% | $-154.0K | -0.1% |
| Q4 FY2024 | $129.2M | — | $7.4M | 5.7% |
| Q3 FY2024 | $134.4M | +7.2% | $11.7M | 8.7% |
| Q2 FY2024 | $130.6M | +2.1% | $9.0M | 6.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.6M | $134.4M | $129.2M | $123.6M | $130.2M | $134.5M | $138.3M | $121.8M |
| YoY Growth | 2.1% | 7.2% | N/A | -4.7% | -0.3% | 0.1% | 7.0% | -1.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $597.8M | $600.5M | $585.1M | $591.5M | $602.1M | $591.4M | $584.0M | $587.7M |
| Liabilities | $357.5M | $349.7M | $338.6M | $338.1M | $340.8M | $320.0M | $318.0M | $312.6M |
| Equity | $240.3M | $250.7M | $246.6M | $253.4M | $261.3M | $271.3M | $266.0M | $275.1M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $17.1M | $13.1M | $20.6M | $6.7M | $13.9M | $8.5M | $7.9M | $4.0M |